What is the confirmed market size and growth trajectory for the global healthcare logistics market?
The market was valued at USD 105.8 billion in 2025 and is projected to grow at a CAGR of 6.0% to USD 178.75 billion by 2035. Cold chain logistics is the dominant and fastest-growing function. Air transportation is dominant by shipment value. Pharmaceutical manufacturers are the largest end-user. Biopharmaceutical manufacturers are the fastest-growing end-user. Biopharmaceuticals (biologics and biosimilars) are the fastest-growing product type. Temperature-controlled logistics is dominant. International destination is the fastest-growing. North America and Europe lead; Asia-Pacific is fastest-growing.

How is cell and gene therapy logistics creating an entirely new healthcare logistics infrastructure category?
Cell and gene therapies — requiring cryogenic storage at -70°C to -196°C liquid nitrogen temperatures, single-patient chain-of-custody documentation, and delivery against clinical administration schedule windows — create logistics requirements that have no precedent in conventional pharmaceutical cold chain infrastructure. Each cell and gene therapy shipment can represent USD 50,000 to USD 500,000 in product value at risk, and logistics failure can result in patient harm from missed treatment windows or product destruction — making cell and gene therapy logistics the most technically demanding and highest-value healthcare logistics category.

How do the three major pharmaceutical distributors — McKesson, Cencora, and Cardinal Health — define the healthcare logistics market structure?
The three largest U.S. pharmaceutical distributors — McKesson, Cencora, and Cardinal Health — collectively distribute over 90% of U.S. prescription pharmaceutical volume, creating a distribution infrastructure of 80-plus distribution centres, 350,000-plus retail pharmacy customers, and specialty pharmaceutical networks serving hospitals, oncology practices, and specialty clinics. This concentrated distribution model reflects the capital intensity and regulatory compliance requirements of GDP-compliant pharmaceutical distribution at national scale.

What GDP compliance requirements create the regulatory barrier sustaining healthcare logistics premium pricing?
Good Distribution Practice compliance — requiring temperature mapping validation, qualified cold chain equipment, deviation management procedures, staff training documentation, and regulatory authority inspection readiness — creates a compliance barrier that non-specialist logistics operators cannot meet without multi-year infrastructure and procedure investment. The cost of GDP non-compliance — including product destruction, FDA warning letters, and product recall liability — creates shipper willingness to pay GDP-compliant logistics premiums that sustain above-market healthcare logistics pricing.

What is driving specialty drug distribution as the fastest-growing healthcare logistics product type?
Specialty drugs — high-cost, biologics-based therapies including monoclonal antibodies, gene therapies, CAR-T therapies, and specialty small molecules — require controlled 2°C-8°C distribution, patient-specific dispensing, and hub-and-spoke specialty pharmacy networks that differ fundamentally from conventional retail pharmacy distribution. The specialty drug market represents approximately 55% of U.S. drug spend on approximately 2% of prescription volume — creating disproportionate healthcare logistics revenue concentration per specialty therapy unit distributed.

How does reverse logistics within healthcare create the most regulated and highest-liability reverse supply chain operation?
Pharmaceutical reverse logistics — managing expired medicine collection, controlled substance return and DEA-certified destruction, product recall logistics, and returned serialised product track-and-trace reconciliation — requires DEA registration, state pharmaceutical board compliance, certified destruction documentation, and full DSCSA serialisation tracking through disposal — creating regulatory compliance requirements that are more complex and higher-liability than any other reverse logistics operation in any industry.